惠泰医疗: 关于公司放弃部分优先购买权、向控股公司增资构成与关联方共同投资暨关联交易的公告

Core Viewpoint - The announcement details Shenzhen Huatai Medical Instrument Co., Ltd.'s decision to waive part of its preemptive rights and to increase capital in its subsidiary, Hunan Yiweidi Medical Instrument Co., Ltd., which constitutes a related party transaction [1][2][3] Summary by Sections Transaction Overview - Hunan Yiweidi is a subsidiary of Huatai Medical, with Huatai holding 42.3380% directly and controlling 68.9512% through a private equity fund [1] - The transaction involves the transfer of 10% of Yiweidi's shares and a capital increase of RMB 50 million, with RMB 1,114.8714 million allocated to registered capital and RMB 38,851,286 allocated to capital reserves [1][3] - The transaction does not constitute a major asset restructuring and has no significant legal obstacles [1][2] Related Party Transaction - The transaction was approved in meetings held on July 7, 2025, and requires shareholder approval [1][6] - The involved parties include related entities Shanghai Huishen and Shanghai Huizhen, which are linked to the company's directors and senior management [3][5] Financial Details - The overall pre-investment valuation of Yiweidi is set at RMB 130 million [5] - The financial data for related entities shows Shanghai Huishen with total assets of approximately RMB 155.5 million and net profit of RMB 240.36 million for the last fiscal year [3][4] Strategic Importance - The transaction aims to enhance Yiweidi's competitiveness and operational efficiency, aligning with Huatai's strategic focus on core business areas such as electrophysiological devices and peripheral vascular intervention products [5] - The capital increase and share transfer are designed to optimize Yiweidi's shareholder structure and governance, promoting synergy between Huatai and Yiweidi [5][6] Approval Process - The transaction has undergone a rigorous internal review process to ensure fair pricing and compliance with regulations, with related directors abstaining from voting [6][7]